Cell line · CVCL_7256
Papers22
74 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
1 to 20 of 22
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Stimulate-and-retain hydrogel strategy integrating oncolytic virus and oxaliplatin for dual ICD-inducing antitumor immunity. | Acta Pharm Sin B | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Microbial induction of MHC-II expression in colon cancer cells overcomes immunotherapy resistance and limits metastasis. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Licoisoflavone A potentiates oxaliplatin efficacy in colorectal cancer by dual targeting arginine metabolism of tumor microenvironment and cancer cells. | Chin Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Characterization and evaluation of a novel polylactic acid-made bioreactor for large-scale adherent cell expansion. | Appl Microbiol Biotechnol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Real-Time In Vivo Cellular-Level Imaging During Puncture. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tumor-infiltrating bacteria disrupt cancer epithelial cell interactions and induce cell-cycle arrest. | Cancer Cell | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Novel Chimeric CTLA-4 B-cell Epitope Peptide Vaccines Demonstrate Effective Antitumor Immunity with/without PD1/PDL1 Blockade in Multiple Syngeneic Murine Models of Breast and Colorectal Cancers. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| ISCOM-type matrix from beta-escin and glycyrrhizin saponins. | Heliyon | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Moderate-intensity aerobic exercise training improves CD8+ tumor-infiltrating lymphocytes effector function by reducing mitochondrial loss. | iScience | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| MIIP downregulation drives colorectal cancer progression through inducing peri-cancerous adipose tissue browning. | Cell Biosci | 2024 | Its Methods give the RRID and name the line | PubMed | |
| S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells. | Mol Cancer Ther | 2023 | Its Methods give the RRID and name the line | PubMed | |
| AZD4625 is a Potent and Selective Inhibitor of KRASG12C. | Mol Cancer Ther | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Selective targeting of the TLR4 co-receptor, MD2, prevents colon cancer growth and lung metastasis. | Int J Biol Sci | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Interlaboratory study to validate a STR profiling method for intraspecies identification of mouse cell lines. | PLoS One | 2019 | Cellosaurus cites it | PubMed | |
| Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation. | Cancer Cell | 2019 | Its Methods give the RRID and name the line | PubMed | |
| In situ administration of cytokine combinations induces tumor regression in mice. | EBioMedicine | 2018 | Its Methods give the RRID and name the line | PubMed | |
| Molecular cytogenetic characterization of two murine colorectal cancer cell lines. | 2018 | Cellosaurus cites it | DOI | ||
| SNP array profiling of mouse cell lines identifies their strains of origin and reveals cross-contamination and widespread aneuploidy. | BMC Genomics | 2014 | Cellosaurus cites it | PubMed | |
| Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. | BMC Genomics | 2014 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_7256/papers